# Aktis Oncology, Inc. Common stock (AKTS)

> Aktis Oncology, Inc. Common stock (AKTS) trades at $16.10 (-1.29%) as of 4:12:59 AM EST on Nov 19, 2026, +0.12% over the past month. Market cap is $898.35M, with 16.0 days to cover in short interest.

Canonical: https://massive.com/quote/akts
Data as of: 2026-11-19T09:12:59.071Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$16.10** -0.21 (-1.29%)
As of 4:12:59 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Aktis Oncology, Inc. Common stock (AKTS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -1.29% |
| 1W | -5.52% |
| 1M | +0.12% |
| YTD | -28.12% |
| 1Y | -28.12% |
| 52-wk range | $13.96 – $34.19 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for AKTS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $16.08 – $16.71 |
| Open | $16.30 |
| Prev close | $16.31 |
| Volume | 435.02K |
| Market cap | $898.35M |
| Shares out | 55.8M |

## Valuation and profitability ratios

Valuation and profitability ratios for Aktis Oncology, Inc. Common stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 74.27 |
| P/B | 1.96 |
| P/FCF | — |
| ROE | -19.2% |
| ROA | -16.5% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Aktis Oncology, Inc. Common stock (AKTS) insider trading](https://massive.com/quote/akts/insider-trading.md): open-market Form 4 buys and sells by Aktis Oncology, Inc. Common stock insiders over the last 12 months.

## 8-K filings

Material corporate events Aktis Oncology, Inc. Common stock has disclosed to the SEC on Form 8-K.

- Nov 12, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 12, 2026, Aktis Oncology, Inc. issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026.”
- Apr 16, 2026 · Director departure
  “On April 15, 2026, each of Helen S. Kim and Oleg Nodelman notified the Board of their decision to resign from their respective positions as members of the Board and all committees thereof, effective as of May 20, 2026. Ms. Kim and Mr. Nodelman's resignations are not due to any disagreement with the Company relating to any of the Company's operations, policies or practices.”
- Jan 12, 2026 · Charter amendment
  “The Company filed its amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware. The Amended and Restated Certificate amends and restates the Company's existing sixth amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 480,000,000 shares of Common Stock and 10,000,000 shares of Class A common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock; (iv) require the approval of at least two-thirds of the shares entitled to vote to remove a director for cause; (v) establish a classified Board; and (vi) eliminate the ability of the Company's stockholders to take action by consent in lieu of a meeting.”
- Dec 17, 2024 · [Voluntary bankruptcy](https://massive.com/quote/sec-filings/8-k/bankruptcy-filings.md)
  “The Notice informed the Company that, pursuant to the discretionary authority granted to Nasdaq under Listing Rule 5110(b), the Company's previously disclosed seeking of voluntary protection under chapter 11 of the United States Bankruptcy Code would serve as an additional basis for delisting the Company's common stock.”
- Dec 16, 2024 · Debt acceleration
  “The filing of the Bankruptcy Petitions described in Item 1.03 above constitutes an event of default under the indenture (the "Indenture"), dated June 9, 2022, among the Company, Akoustis, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (the "Trustee"), governing the Company's 6.0% Convertible Senior Notes due 2027 (the "Convertible Notes"). As of December 16, 2024, the aggregate, principal amount of outstanding Convertible Notes was $44,000,000. Pursuant to the Indenture, upon the occurrence of this event of default, all of the outstanding Convertible Notes became due and payable immediately without further action or notice.”

## Dividend history and stock splits

Aktis Oncology, Inc. Common stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1.094891-for-1 · Apr 24, 2015

## AKTS short interest

How heavily AKTS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 16.0 |
| Short interest | 4.43M |
| Avg volume | 276.24K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## AKTS news

The latest news and headlines about Aktis Oncology, Inc. Common stock (AKTS).

- [Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?](https://www.zacks.com/stock/news/3028106/does-aktis-akts-have-the-potential-to-rally-105-62-as-wall-street-analysts-expect?cid=CS-ZC-FT-fundamental_analysis|consensus_price_target-3028106) · Zacks Investment Research · Nov 11, 2026 · positive sentiment
- [Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company](https://www.fool.com/coverage/filings/2026/05/13/why-this-biotech-fund-opened-a-usd9-million-position-in-a-newly-public-cancer-company/?source=iedfolrf0000001) · The Motley Fool · May 13, 2026 · positive sentiment
- [Aktis Oncology to Present at the BofA Securities Health Care Conference](https://www.globenewswire.com/news-release/2026/05/06/3288736/0/en/Aktis-Oncology-to-Present-at-the-BofA-Securities-Health-Care-Conference.html) · GlobeNewswire Inc. · May 6, 2026 · positive sentiment
- [Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting](https://www.globenewswire.com/news-release/2026/04/21/3278532/0/en/Aktis-Oncology-Announces-Presentation-of-First-Clinical-Imaging-and-Dosimetry-Data-for-AKY-2519-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html) · GlobeNewswire Inc. · Apr 21, 2026 · positive sentiment
- [A Fresh IPO That Long-Term Investors Shouldn’t Ignore](https://www.investing.com/analysis/a-fresh-ipo-that-longterm-investors-shouldnt-ignore-200673246) · Investing.com · Jan 14, 2026 · positive sentiment

## About Aktis Oncology, Inc. Common stock

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 79 |
| IPO | $18.00 on Jan 9, 2026 |

[Aktis Oncology IPO page](https://massive.com/quote/akts/ipo.md)

[Company website](https://www.aktisoncology.com)

## FAQ

### What is the Aktis Oncology, Inc. Common stock (AKTS) stock price today?

Aktis Oncology, Inc. Common stock (AKTS) is trading at $16.10 (-1.29% on the day) as of 4:12:59 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Aktis Oncology, Inc. Common stock?

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies.

### What is the short interest in AKTS?

As of Oct 30, 2026, AKTS has 4.43M shares short and 16.0 days to cover.

### What exchange is AKTS listed on?

Aktis Oncology, Inc. Common stock (AKTS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time AKTS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=AKTS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Aktis Oncology, Inc. Common stock (AKTS) insider trading](https://massive.com/quote/akts/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
